HOSHINO Junichi
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Professor and Division head |
|
Article types | Original article |
Language | English |
Peer review | Non peer reviewed |
Title | がん薬物療法時の腎障害診療ガイドライン2022(第4章) がんサバイバーのCKD治療(Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022) |
Journal | Formal name:International Journal of Clinical Oncology Abbreviation:Int J Clin Oncol ISSN code:14377772/13419625 |
Domestic / Foregin | Foregin |
Publisher | シュプリンガー・ジャパン(株) |
Volume, Issue, Page | 28(10),pp.1333-1342 |
Author and coauthor | Ishikura Kenji, Omae Kenji, Sasaki Sho, Shibagaki Yugo, Ichioka Satoko, Okuda Yusuke, Koitabashi Kenichiro, Suyama Koichi, Mizukami Takuro, Kondoh Chihiro, Hirata Sumio, Matsubara Takeshi, Hoshino Junichi, Yanagita Motoko |
Publication date | 2023/10/28 |
Summary | Chronic kidney disease (CKD) is one of the most disabling disorders with significant comorbidity and mortality. Incidence and prevalence of CKD in cancer survivors are remarkably high in both adults and pediatric patients. The reasons for this high incidence/prevalence are multifold but kidney damage by cancer itself and cancer treatment (pharmacotherapy/surgery/radiation) are the main reasons. Since cancer survivors commonly have significant comorbidities, risk of cancer recurrence, limited physical function or life expectancy, special attentions should be paid when considering the treatment of CKD and its complications. Especially, shared decision-making should be considered when selecting the renal replacement therapies with as much information/facts/evidence as possible. |
DOI | 10.1007/s10147-023-02375-1 |
Document No. | XA19140005<Pre 医中誌> |
PMID | 37418141 |